TG Therapeutics starts Phase 2 trial of Briumvi for schizophrenia

July 6, 2026 7:31 AM

TG Therapeutics, Inc. (NASDAQ: TGTX) announced the initiation of a Phase 2 clinical trial evaluating Briumvi (ublituximab-xiiy) in adults with ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found